CHICAGO (Reuters) - Edwards LifeSciences Corp's less-invasive replacement heart valve alleviates symptoms such as fatigue and breathlessness better than standard medical therapy, data released on Monday show.
Researchers evaluated the symptoms in patients from the company's successful Partner trial, whose key results on mortality were released in September. Those data showed Edwards' Sapien valve, which is threaded through the arteries to the heart, sharply reduced death rates at one year compared with patients who received only the standard therapy of medicine or an angioplasty procedure.